Oncology

CAR-T cells attacking a cancer cell
#Advanced Therapies #CAR-T #Cell therapy #Lyell Immunopharma #Lymphoma #Oncology #Phase III trial

CAR-Ts go head-to-head in first-of-its-kind clinical trial

Lyell Immunopharma has begun its PiNACLE – H2H Phase III trial evaluating rondecabtagene autoleucel (ronde-cel, also known as LYL314) compared to lisocabtagene maraleucel (liso-cel) or axicabtageneciloleucel (axi-cel).  The CAR-T therapies will be assessed in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving treatment in the second-line… Read More

#Cancer Research #News #Trending News

Molecular glues
#Molecular glue degrader #Neomorph #Oncology #Phase I trial

Novel molecular glue degrader therapy reaches first patients

Neomorph has commenced a Phase I/II clinical trial evaluating NEO-811, a novel investigational molecular glue degrader, in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC).  NEO-811 is an investigational molecular glue degrader designed to induce targeted degradation of a key disease-driving protein… Read More

#Cancer Research #News

Nucleolus of the cell
#Cancer treatment #Oncology #RNA #Texas A&M University Health Science Center

Researchers identify RNA linked to cancer survival

Researchers at the Texas A&M University Health Science Center have identified a novel RNA molecule that plays a crucial role in preserving the integrity of a key cellular structure, nucleolus.  This research reveals an RNA molecule that regulates key cellular functions without turning into protein, thus functioning… Read More

#Cancer Research #Editor's Choice #News

#Assays #Drug discovery #Oncology #Revvity #SLAS2026 #SPT Labtech

SLAS2026: Day One Round-Up  

DDW covers some of the biggest announcements from the first day of SLAS2026.     Carterra launches high-throughput SPR instrument   High-throughput technology provider Carterra  launched its Carterra Vega High-Throughput Surface Plasmon Resonance (HT-SPR) instrument – the industry’s first 48-channel SPR platform. The instrument has been designed to deliver 12-fold higher throughput versus the… Read More

#News

Modern medical science laboratory
#Cancer research #High throughput screening #Oncology #SPT Labtech

SPT Labtech & BellBrook Labs collaborate on oncology 

SPT Labtech and BellBrook Labs are collaborating to advance cancer research, having developed a miniaturised, high-throughput screening platform for the discovery and profiling of Vacuolar protein sorting associated protein 4B (VPS4B) ATPase inhibitors.   VPS4B has emerged as a high-priority therapeutic target in oncology due to its overexpression in specific tumours and its… Read More

#Cancer Research #News

#Oncology #Syncona #The Francis Crick Institute

ALTx Therapeutics launched to develop novel cancer treatments 

Slingshot Therapeutics has launched ALTx Therapeutics with funding worth £12.55 million ($17.04 million) to develop novel treatments for cancer.  ALTx Therapeutics launched into the Slingshot accelerator with backing from Syncona, the Francis Crick Institute and Cancer Research Horizons.  Spinning out of the Crick, ALTx is focused on developing therapeutics targeting vulnerabilities in cancers that rely on… Read More

#Business & Investment #Cancer Research #News

The European Medicines Agency building
#CHMP #European Medicines Agency #Oncology

CHMP recommends combination therapy to treat anal cancer  

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended Zynyz (retifanlimab) for the treatment of anal cancer.  Zynyz, developed by biopharmaceutical company Incyte, has received the EMA’s positive opinion to treat recurrent squamous cell carcinoma of the anal cancer (SCAC) in combination with… Read More

#Cancer Research #News

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

T cells attack a cancer cell
#CHMP #European Commission #Immunotherapy #Incyte #Oncology

CHMP recommends first PD-1 immunotherapy for rare cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy).  If it is approved by the European Commission it will be the first PD-1 immunotherapy treatment… Read More

#News #Regulatory

Male patient with doctor
#CHMP #European Commission #Johnson & Johnson #Oncology #Prostate cancer

J&J drug gets EU green light for prostate cancer

Johnson & Johnson’s Akeega (niraparib and abiraterone acetate dual action tablet) could soon be available to EU patients with metastatic hormone-sensitive prostate cancer with BRCA1/2 mutations, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).  The recommendation is for niraparib and abiraterone acetate with prednisone… Read More

#News #Regulatory

#Advanced Therapies #Brain cancer #FDA #Gene therapy #Oncology #Phase I trial #Siren Biotechnology

FDA clears first cancer gene therapy for trials

The US Food and Drug Administration (FDA) has cleared Siren Biotechnology’s first Investigational New Drug (IND) application for its AAV immuno-gene therapy for cancer, enabling the initiation of its first-in-human clinical trial.  The IND clearance supports the evaluation of Siren’s lead investigational programme in adult patients with recurrent high-grade glioma.  … Read More

#Cancer Research #Editor's Choice #News #Regulatory

#Artificial intelligence (AI) #Colorectal cancer #KRAS #Oncology #Oxford Drug Design

Oxford Drug Design validates cancer therapeutic mechanism

AI drug discovery company Oxford Drug Design has successfully completed in vivo validation of a novel therapeutic approach targeting multiple tumour types. In studies using a genetically engineered mouse model that replicates the earliest mutational events in colorectal cancer, Oxford Drug Design’s lead compound demonstrated statistically significant anti-tumour… Read More

#Cancer Research #News

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

Pancreatic cancer
#Oncology #Pancreatic cancer #Tokyo University of Science #Tumour microenvironment (TME)

Potential tumour-suppressing gene identified in pancreatic cancer

A new study has revealed that low levels of CTDNEP1 may drive early and deadly pancreatic tumours, highlighting its role as a tumour suppressor.  Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining the pancreatic duct. Accounting for… Read More

#Cancer Research #News

Ovarian cancer cells
#Corcept Therapeutics #Oncology #Ovarian cancer #Phase III trial

Ovarian cancer drug reduces risk of death by 35%

Corcept Therapeutics has announced that ROSELLA, the company’s Phase III trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint.  In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 35% reduction in the risk of… Read More

#Cancer Research #Editor's Choice #News

#Bristol Myers Squibb #Collaboration #Janux Therapeutics #Oncology #Solid tumours

Janux and Bristol Myers Squibb partner on tumour-activated therapeutic

Bristol Myers Squibb and immunotherapy developer Janux Therapeutics have announced a collaboration and exclusive worldwide license agreement.   Under the terms of the agreement, the companies will develop an undisclosed, novel, tumour-activated therapeutic targeting a validated solid tumour antigen expressed across several human cancer types.  Janux may receive up to $50… Read More

#Business & Investment #Cancer Research #News